Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes

This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (<30, 30–35 and >35 kg/m(2)) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolffenbuttel, B. H. R., Van Gaal, L., Durán‐Garcia, S., Han, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111732/
https://www.ncbi.nlm.nih.gov/pubmed/27027802
http://dx.doi.org/10.1111/dom.12669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111732/
https://www.ncbi.nlm.nih.gov/pubmed/27027802
http://dx.doi.org/10.1111/dom.12669

Ejemplares similares